Sweden Atopic Dermatitis Drugs Market Size & Outlook
The atopic dermatitis drugs market in Sweden is expected to reach a projected revenue of US$ 306.1 million by 2033. A compound annual growth rate of 8.6% is expected of Sweden atopic dermatitis drugs market from 2026 to 2033.
Revenue, 2025 (US$M)
$156.6
Estimate, 2026 (US$M)
$172.1
Forecast, 2033 (US$M)
$306.1
CAGR, 2026 - 2033
8.6%
Global Market
Related Markets
Sweden atopic dermatitis drugs market highlights
- The Sweden atopic dermatitis drugs market generated a revenue of USD 156.6 million in 2025 and is expected to reach USD 306.1 million by 2033.
- The Sweden market is expected to grow at a CAGR of 8.6% from 2026 to 2033.
- In terms of segment, biologics was the largest revenue generating drug class in 2025.
- PDE4 Inhibitors is the most lucrative drug class segment registering the fastest growth during the forecast period.
Atopic dermatitis drugs market data book summary
| Market revenue in 2025 | USD 156.6 million |
| Market revenue in 2033 | USD 306.1 million |
| Growth rate | 8.6% (CAGR from 2026 to 2033) |
| Largest segment | Biologics |
| Fastest growing segment | PDE4 Inhibitors |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Biologics |
| Key market players worldwide | Pfizer Inc, Sanofi SA, AbbVie Inc, Galderma Group AG Registered Shares, Eli Lilly and Co, Regeneron Pharmaceuticals Inc, Otsuka Holdings Co Ltd, Novartis AG ADR, Incyte Corp, LEO Pharma |
Other key industry trends
- In terms of revenue, Sweden accounted for 0.8% of the global atopic dermatitis drugs market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Europe, Germany atopic dermatitis drugs market is projected to lead the regional market in terms of revenue in 2033.
- France is the fastest growing regional market in Europe and is projected to reach USD 1,566.1 million by 2033.
No credit card required*
Publish Date: Jun 11, 2026
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Atopic Dermatitis Drugs Market Scope
Atopic Dermatitis Drugs Market segmentation & scope
Atopic Dermatitis Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Novartis AG ADR | View profile | 76,057 | Lichtstrasse 35, Basel, Switzerland, 4056 | www.novartis.com |
| Otsuka Holdings Co Ltd | View profile | 39,548 | 2-9 Kanda-Tsukasamachi, Chiyoda-ku, Tokyo, Japan, 101-0048 | www.otsuka.com/jp |
| AbbVie Inc | View profile | 50,000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | www.abbvieinvestor.com |
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Sanofi SA | View profile | 87,994 | 46, avenue de la Grande Armée, Paris, France, 75017 | www.sanofi.com |
| Galderma Group AG Registered Shares | View profile | - | Zählerweg 10, Zug, Switzerland, 6300 | www.galderma.com |
| Eli Lilly and Co | View profile | 43,000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | www.lilly.com |
| Regeneron Pharmaceuticals Inc | View profile | 13,450 | 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707 | www.regeneron.com |
| Incyte Corp | View profile | 2,524 | 1801 Augustine Cut-Off, Wilmington, DE, United States, 19803 | www.incyte.com |
| LEO Pharma | View profile | 1001-5000 | Parsippany, New Jersey, United States, North America | www.leo-pharma.us/ |
Sweden Atopic Dermatitis Drugs Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Atopic Dermatitis Drugs Market Outlook will help companies and investors design strategic landscapes.
Biologics was the largest segment with a revenue share of 48.08% in 2025.
Horizon Databook has segmented the Sweden atopic dermatitis drugs market based on corticosteroids, calcineurin inhibitors, pde4 inhibitors, biologics covering the revenue growth of each sub-segment from 2021 to 2033.
- Sweden Atopic Dermatitis Drugs Market Drug Class Outlook (Revenue, USD Million , 2021-2033)
- Corticosteroids
- Calcineurin Inhibitors
- PDE4 Inhibitors
- Biologics
- Others
- Sweden Atopic Dermatitis Drugs Market Route of Administration Outlook (Revenue, USD Million , 2021-2033)
- Topical
- Parenteral
- Oral
- Sweden Atopic Dermatitis Drugs Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Others
Reasons to subscribe to Atopic Dermatitis Drugs Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Atopic Dermatitis Drugs Market Outlook databook
- Our clientele includes a mix of Atopic Dermatitis Drugs Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Sweden Atopic Dermatitis Drugs Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Sweden Atopic Dermatitis Drugs Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Sweden Atopic Dermatitis Drugs Market, 2021-2033 (US$M)
Sweden Drug Class - Atopic Dermatitis Drugs Market Statistics, 2025 - 2033 (US$M)
